Disease: Essential thrombocytosis
- A Case of acute Myocardial Infarction in a Patient with Essential Thrombocythaemia Treated with Anagrelide
- A Case of JAK2V617F-Negative Myeloproliferative Neoplasm in a Young Female Presenting With Extreme Thrombocytosis
- A case of lower limb ulcer caused by hydroxyurea in treating primary thrombocytosis
- A Case of Porto-Sinusoidal Vascular Disease
- A germline <em>JAK2</em> exon12 mutation and a late somatic <em>CALR</em> mutation in a patient with essential thrombocythemia
- A germline JAK2 exon12 mutation and a late somatic CALR mutation in a patient with essential thrombocythemia
- A rare case of essential thrombocythemia with pseudo-hyperkalemia
- A Rare Coexistence of Smoldering Multiple Myeloma and JAK2-Positive Myeloproliferative Neoplasm: A Case of Dual Synchronous Hematological Malignancy
- A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery
- Aberrant Platelet Aggregation as Initial Presentation of Essential Thrombocythemia: Failure of Entero-Coated Aspirin to Reduce Platelet Hyperactivation
- Acquired von Willebrand Syndrome in a 17-Year-Old With Essential Thrombocythemia: A Case Report With Literature Review
- Acute invasive fungal sinusitis with orbital tip syndrome in patients on long-term use of ruxolitinib: a case report
- ADAMTS13, von Willebrand Factor, Platelet Microparticles, Factor VIII, and Impact of Somatic Mutations in the Pathogenesis of Splanchnic Vein Thrombosis Associated with BCR-ABL-Negative Myeloproliferative Neoplasms
- AI Differentiates Two Similar Blood Cancers
- An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis
- Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms
- Analysis of the factors influencing the severity of coronavirus disease 2019 in patients with myeloproliferative neoplasms based on an online questionnaire
- Bleeding heralding the diagnosis of essential thrombocythemia
- Bone infarction: A rare complication of essential thrombocytosis with JAK2-V617F mutation
- Broad next generation integrated sequencing of myelofibrosis identifies disease-specific and age-related genomic alterations
- Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations
- CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia
- CALR mutation burden in essential thrombocythemia and disease outcome
- CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM
- Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms
- Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome
- Childbirth rates in women with myeloproliferative neoplasms
- CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidties
- Chronic myeloproliferative neoplasms with concomitant <em>CALR</em> mutation and <em>BCR::ABL1</em> translocation: diagnostic and therapeutic implications of a rare hybrid disease
- Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study
- Co-occurrence of <em>JAK2-V617 F</em> mutation and <em>BCR::ABL1</em> translocation in chronic myeloproliferative neoplasms: a potentially confounding genetic combination
- Comparison of Clinical Characteristics of JAK2, CALR and Tri-Negative Driving Mutant Type in Patients with Essential Thrombocythemia
- Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression
- Correction to: Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience
- Correction to: Correlation between IPSET‑t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience
- Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience
- Cytoreduction for ET and PV: who, what, when, and how?
- Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms
- Detecting Multiple Driver Mutations in a Patient with Essential Thrombocythemia
- Development and validation of a model for the early prediction of progression from essential thrombocythemia to post-essential thrombocythemia myelofibrosis: a multicentre retrospective study
- Diagnosis and Therapy in MCT8 Deficiency: Ongoing Challenges
- Digital gangrene: can be the first manifestation of essential thrombocythemia? a case report
- Direct and indirect costs for patients with myeloproliferative neoplasms
- Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience
- Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management
- Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
- Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
- Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients
- Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology
- Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia
- Homozygous Sickle Cell Disease after Age of 40: Follow-Up of a Cohort of 209 Patients in Senegal, West Africa
- How I treat myeloproliferative neoplasms in pregnancy
- Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
- Impact of Hydroxyurea to Treat Haematological Disorders on Male Fertility: Two Case Reports and a Systematic Review
- Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm
- Inherited polygenic effects on common hematological traits influence clonal selection on JAK2<sup>V617F</sup> and the development of myeloproliferative neoplasms
- Insights into the role of JAK2-I724T variant in myeloproliferative neoplasms from a unique cohort of New Zealand patients
- Interferons in the treatment of myeloproliferative neoplasms
- JAK2-V617F-mutated myeloproliferative neoplasms: A cannot be missed cause of symptomatic postoperative epidural hematoma after lumber spine surgery
- JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms
- JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms
- Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report
- Merkel Cell Carcinoma on the Face: A Case Report
- Merkel Cell Carcinoma on the Face: Case Report
- Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
- Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives
- Myeloproliferative Neoplasms: Diseases Mediated by Chronic Activation of Signal Transducer and Activator of Transcription (STAT) Proteins
- Near-early T-cell precursor acute lymphoblastic leukemia following a diagnosis of essential thrombocythemia
- Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study
- Newly identified roles for PIEZO1 mechanosensor in controlling normal megakaryocyte development and in primary myelofibrosis
- One thousand patients with essential thrombocythemia: the Florence-CRIMM experience
- One thousand patients with essential thrombocythemia: the Mayo Clinic experience
- Percutaneous mesocaval shunt creation for portal thrombosis in a patient with a JAK2V617F mutation
- Platelet Factor 4 and Longevity of Patients with Essential Thromobocythemia: An Example of Antagonistic Pathogenic Pleiotropy
- Polycythemia vera and essential thrombocythemia of intermediate-age: A real-life, multicenter analysis of first-line treatment approach
- Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients
- Presence and Onset of Chronic Kidney Disease as a Factor Involved in the Poor Prognosis of Patients with Essential Thrombocythemia
- Prolonged Proton Pump Inhibitor Use and Thrombohemorrhagic Risk in Essential Thrombocythemia and Polycythemia Vera Patients Treated with Long-Term Aspirin: A Pilot Study
- Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic Scores
- Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
- Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms
- Recurrent left ventricular thrombus due to essential thrombocythemia complicated by COVID-19
- Red Blood Cell Contribution to Thrombosis in Polycythemia Vera and Essential Thrombocythemia
- Renal tubular necrosis associated with anagrelide administration: a case report
- Resveratrol and tetrahydroisoquinoline effects on neutrophil sensitivity to NETosis formation in low-risk essential thrombocythemia patients
- Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
- Retinochoroiditis secondary to Rickettsia typhi infection: a case report
- Risk of hepatitis B reactivation in patients with myeloproliferative neoplasms treated with ruxolitinib
- Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study
- ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options
- Sailing in deceptive calm: Navigating the undercurrents of essential thrombocythaemia
- Sex-specific impact on disease outcome and the mutational landscape in essential thrombocythemia: A retrospective cohort study
- SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms
- SOHO State of the Art Updates and Next Questions | Diagnosis, Outcomes, and Management of Prefibrotic Myelofibrosis
- Splanchnic venous thrombosis and recurrent spontaneous abortion due to latent essential thrombocytosis revealed after 20 years: Case report
- Study of significance of bone marrow microvessel density in myeloproliferative neoplasms in correlation with CD34 blasts, mast cell count and fibrosis
- Successful management of VTE with essential thrombocythemia and cavernous transformation of the portal vein in early pregnancy: a case report
- The personal impact of living with a myeloproliferative neoplasm
- The Role of DNA Repair (<em>XPC</em>, <em>XPD</em>, <em>XPF</em>, and <em>XPG)</em> Gene Polymorphisms in the Development of Myeloproliferative Neoplasms
- Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis